--- title: 'Scientist I, Biology at Korro Bio' canonical: 'https://feeny.ai/job/scientist-i-biology-korro-bio-cambridge-pzpjf9tzns7j' type: 'job' last_seen: '2026-09-12' --- # Scientist I, Biology at Korro Bio - **Company:** Korro Bio - **Location:** Cambridge, MA - **Compensation:** $120k–$145k - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-08-27 - **Last confirmed live:** 2026-09-12 - **Apply:** https://jobs.lever.co/korrobio/3b9dc977-ba3e-4766-a57b-b8534a639582 ## Job description Company Summary: Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health. Korro Bio is seeking a highly motivated Scientist I to join our biology group and work with an enthusiastic team of highly skilled scientists. The ideal candidate for this lab-based position will have a strong background in cell and molecular biology, with demonstrated independence in assay development and problem solving. This is an exciting opportunity to be part of a collaborative team and contribute to the development of innovative RNA editing therapeutics in a fast-paced biotech company. Key Responsibilities: - Independently design, develop, and execute a range of functional cell-based assays to validate novel targets, elucidate mechanisms of action, and demonstrate pharmacological activity in liver-relevant disease contexts. - Establish and maintain primary hepatocyte cultures, iPSC-derived hepatocytes, and complex co-culture systems to generate robust functional readouts. - Collaborate closely with the in vivo pharmacology team to design and execute ex vivo assays that characterize the pharmacodynamic effects of compounds, including target engagement, pathway modulation, and downstream biomarker readouts. - Analyze and interpret complex datasets from multiple sources, draw conclusions, and maintain detailed, accurate lab records through Electronic Lab Notebook. - Support operations team in troubleshooting, equipment maintenance and CRO management. - Serve as a key biology contributor at the program team level; clearly present data, findings, and interpretation, and propose next steps informed by ongoing review of relevant scientific literature to cross-functional teams and company leadership. - Work effectively with platform, data science, high-throughput screening, in vivo pharmacology and DMPK teams and deliver high-quality results in a timely fashion. - Guide and mentor junior team members in the planning and execution of scientific experiments. Required Qualifications: - Ph.D. in cell biology, molecular biology, biochemistry, pharmacology, or a related field; or M.S. with 6–9+ years of relevant experience. - Demonstrated hands-on expertise in mammalian cell culture, including primary cells, iPSCs and co-culture models, with experience in stable cell line engineering. - Proficiency in standard cell biology and molecular biology techniques (e.g., Western blot, ELISA, DNA/RNA extraction, RT-qPCR, immunofluorescence, flow cytometry). - Strong analytical skills with the ability to critically evaluate complex biology problems and translate findings into clear recommendations. - Effectively balances multiple priorities in a fast-paced environment, maintaining rigorous attention to detail and delivering high-quality data within established timelines. - Strong verbal and written communication skills; able to convey complex scientific concepts and findings with clarity to matrixed teams. Preferred Qualifications: - Experience with liver biology, liver disease models or metabolic diseases is highly preferred - Experience with oligonucleotide therapeutics is a strong plus Benefits:  Korro offers competitive compensation, including equity-based compensation, and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, life insurance, a dependent care flexible spending account and a Company-funded health savings account and free parking. ## About Korro Bio ## Company Overview - **One-liner**: Korro Bio is a clinical-stage biotechnology company harnessing the body’s natural RNA editing machinery to develop a new class of genetic medicines for rare and prevalent diseases. - **Entity Type**: Public (Nasdaq: KRRO, IPO November 2023) - **Headquarters**: Cambridge, Massachusetts, USA - **Founded**: 2015 (originally as Frequency Therapeutics, later renamed to Korro Bio) - **Founders**: Nessan Bermingham, Ph.D. (Co-Founder & Chairman) ## Core Business - **Primary industry**: Biotechnology – RNA editing therapeutics - **Target customers**: Patients with debilitating and life-threatening diseases; partners in pharmaceutical R&D (B2B); healthcare providers (B2B/Institutional) - **Mission statement**: “Discover, develop, and commercialize a new class of RNA therapies informed by human genetics and disease biology to improve the lives of patients with debilitating and life-threatening diseases.” [korrobio.com/about-us](https://korrobio.com/about-us/) ## Products & Services - **[OPERA® Platform (Oligonucleotide Promoted Editing of RNA)]**: Proprietary technology that redirects the body’s natural ADAR enzyme to make precise, single-base edits on RNA, enabling repair or creation of functional proteins. Used to discover and develop drug candidates. [korrobio.com](https://korrobio.com/) - **[KRRO-121]**: Lead program – a GalNAc-conjugated RNA editing oligonucleotide for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). Designed to generate a stabilized, de novo glutamine synthetase (GS) protein to clear ammonia. [korrobio.com](https://korrobio.com/) - **[KRRO-111]**: Development candidate for Alpha-1 Antitrypsin Deficiency (AATD). Achieved >90% editing of SERPINA1 transcripts and ~90% repaired functional AAT protein in preclinical studies. Announced May 2026. [linkedin.com/company/korro-bio](https://www.linkedin.com/company/korro-bio) ## Market Standing - **Valuation/Market Cap**: Not disclosed (publicly traded – market cap varies with stock price; no current figure in search results) - **Key Metric (Annual Revenue)**: Not publicly available (estimated $6.4M per some aggregators, but not confirmed in official filings) - **Key Metric (Total Funding)**: USD 479.5 million (including Series A, Series B, and post-IPO equity rounds) [linkedin.com/company/korro-bio](https://www.linkedin.com/company/korro-bio) - **Notable Investors/Partners**: Lead investors include Wu Capital, Venrock Healthcare Capital Partners; also backed by Flagship Pioneering, and others across multiple rounds. - **Growth Signals**: +4.1% monthly headcount growth; 7 active job postings (up 75% month-over-month); addition of KRRO-111 as a development candidate signals pipeline expansion; acquired Frequency Therapeutics in July 2023 for $117M. ## Competitive Advantages - **Proprietary RNA editing technology (OPERA)**: Differentiates from CRISPR-based gene editing by targeting RNA rather than DNA, offering tunability, reversibility, and a potentially better safety profile. - **Broad therapeutic applicability**: Platform can address both rare genetic diseases and more prevalent conditions (e.g., AATD, UCDs), expanding market opportunity. - **Strong intellectual property and scientific talent**: Over 350 scholarly works and 8,800+ citations; 55% of research involves international collaboration. ## Strategic Focus - **Advance lead programs**: Moving KRRO-121 and KRRO-111 toward clinical trials. - **Expand pipeline**: Leverage OPERA platform to target additional indications informed by human genetics. - **Scale organization**: Growing headcount (~70 employees currently) and opening new positions across R&D, clinical, and corporate functions, with a focus on in vivo pharmacology, toxicology, and analytical sciences. [jobs.lever.co/korrobio](https://jobs.lever.co/korrobio) ## Why Work Here - **Culture & Values**: “Driven by purpose and impact” – the company emphasizes collaboration, innovation, and personal growth. Values include relentless curiosity, diversity, transparency, and commitment to delivering results for patients. [korrobio.com/careers](https://korrobio.com/careers/) - **Work Model**: Hybrid and on-site positions available at the Cambridge, MA headquarters (One Kendall Square). Roles like Associate Director, Clinical Supply Chain are listed as hybrid; Principal Scientist, Analytical Sciences is on-site. - **Compensation & Reviews**: Employer rating 3.6/5 (12 reviews); compensation rated 4.3/5, work-life balance 3.8/5, culture 3.3/5. Example salaries: Research Associate II ~$94.7k, Director Computational Biologist ~$138.9k, Associate Scientist ~$108k. - **Perks & Environment**: A “supportive, energetic environment” where hard work is balanced with celebrating achievements. The company fosters space for everyone to succeed and make a real difference in patients’ lives. - **Hiring Transparency**: Uses AI tools to support resume review and candidate assessment, but final decisions are made by humans. [jobs.lever.co/korrobio](https://jobs.lever.co/korrobio) ## Sources 1. [korrobio.com – About Us](https://korrobio.com/about-us/) 2. [korrobio.com – Careers](https://korrobio.com/careers/) 3. [linkedin.com/company/korro-bio](https://www.linkedin.com/company/korro-bio) 4. [jobs.lever.co/korrobio](https://jobs.lever.co/korrobio) 5. [korrobio.com – Homepage](https://korrobio.com/) 6. [Aggregated company data (funding, headcount, reviews) via web search]